Cargando…
End-of-radiation PSA as a novel prognostic factor in patients undergoing definitive radiation and androgen deprivation therapy for prostate cancer
BACKGROUND: In men undergoing definitive radiation for prostate cancer, it is unclear whether early biochemical response can provide additional prognostic value beyond pre-treatment risk stratification. METHODS: Prostate cancer patients consecutively treated with definitive radiation at our institut...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5429233/ https://www.ncbi.nlm.nih.gov/pubmed/28094250 http://dx.doi.org/10.1038/pcan.2016.67 |
_version_ | 1783235983043461120 |
---|---|
author | Narang, Amol K. Trieu, Janson Radwan, Noura Ram, Ashwin Robertson, Scott P. He, Pei Gergis, Carol Griffith, Emily Singh, Harleen DeWeese, Tate A. Honig, Stephanie Annadanam, Anvesh Greco, Stephen DeVille, Curtiland McNutt, Todd DeWeese, Theodore L. Song, Daniel Y. Tran, Phuoc T. |
author_facet | Narang, Amol K. Trieu, Janson Radwan, Noura Ram, Ashwin Robertson, Scott P. He, Pei Gergis, Carol Griffith, Emily Singh, Harleen DeWeese, Tate A. Honig, Stephanie Annadanam, Anvesh Greco, Stephen DeVille, Curtiland McNutt, Todd DeWeese, Theodore L. Song, Daniel Y. Tran, Phuoc T. |
author_sort | Narang, Amol K. |
collection | PubMed |
description | BACKGROUND: In men undergoing definitive radiation for prostate cancer, it is unclear whether early biochemical response can provide additional prognostic value beyond pre-treatment risk stratification. METHODS: Prostate cancer patients consecutively treated with definitive radiation at our institution by a single provider from 1993–2006 and who had an EOR PSA (n=688, median follow-up 11.2 years). We analyzed the association of an end-of-radiation (EOR) prostate-specific antigen (PSA) level, obtained during the last week of radiation, with survival outcomes. Multivariable-adjusted cox proportional hazards models were constructed to assess associations between a detectable EOR PSA (defined as ≥0.1 ng ml(−1)) and biochemical failure-free survival (BFFS), metastasis-free survival (MFS), prostate cancer-specific survival (PCSS), and overall survival (OS). Kaplan-Meier survival curves were constructed, with stratification by EOR PSA. RESULTS: At the end of radiation, the PSA level was undetectable in 30% of patients. Men with a detectable EOR PSA experienced inferior 10-year BFFS (49.7% vs. 64.4%, p<0.001), 10-year MFS (84.8% vs. 92.0%, p=0.003), 10-year PCSS (94.3% vs. 98.2%, p=0.007), and 10-year OS (75.8% vs. 82.5%, p=0.01), as compared to men with an undetectable EOR PSA. Among NCCN intermediate- and high-risk men who were treated with definitive radiation and androgen deprivation therapy (ADT), a detectable EOR PSA was more strongly associated with PCSS than initial NCCN risk level (EOR PSA: HR 5.89, 95% CI 2.37–14.65, p<0.001; NCCN risk level: HR 2.01, 95% CI 0.74–5.42, p=0.168). Main study limitations are retrospective study design and associated biases. CONCLUSIONS: EOR PSA was significantly associated with survival endpoints in men who received treated with definitive radiation and ADT. Whether the EOR PSA can be used to modulate treatment intensity merits further investigation. |
format | Online Article Text |
id | pubmed-5429233 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
record_format | MEDLINE/PubMed |
spelling | pubmed-54292332017-07-17 End-of-radiation PSA as a novel prognostic factor in patients undergoing definitive radiation and androgen deprivation therapy for prostate cancer Narang, Amol K. Trieu, Janson Radwan, Noura Ram, Ashwin Robertson, Scott P. He, Pei Gergis, Carol Griffith, Emily Singh, Harleen DeWeese, Tate A. Honig, Stephanie Annadanam, Anvesh Greco, Stephen DeVille, Curtiland McNutt, Todd DeWeese, Theodore L. Song, Daniel Y. Tran, Phuoc T. Prostate Cancer Prostatic Dis Article BACKGROUND: In men undergoing definitive radiation for prostate cancer, it is unclear whether early biochemical response can provide additional prognostic value beyond pre-treatment risk stratification. METHODS: Prostate cancer patients consecutively treated with definitive radiation at our institution by a single provider from 1993–2006 and who had an EOR PSA (n=688, median follow-up 11.2 years). We analyzed the association of an end-of-radiation (EOR) prostate-specific antigen (PSA) level, obtained during the last week of radiation, with survival outcomes. Multivariable-adjusted cox proportional hazards models were constructed to assess associations between a detectable EOR PSA (defined as ≥0.1 ng ml(−1)) and biochemical failure-free survival (BFFS), metastasis-free survival (MFS), prostate cancer-specific survival (PCSS), and overall survival (OS). Kaplan-Meier survival curves were constructed, with stratification by EOR PSA. RESULTS: At the end of radiation, the PSA level was undetectable in 30% of patients. Men with a detectable EOR PSA experienced inferior 10-year BFFS (49.7% vs. 64.4%, p<0.001), 10-year MFS (84.8% vs. 92.0%, p=0.003), 10-year PCSS (94.3% vs. 98.2%, p=0.007), and 10-year OS (75.8% vs. 82.5%, p=0.01), as compared to men with an undetectable EOR PSA. Among NCCN intermediate- and high-risk men who were treated with definitive radiation and androgen deprivation therapy (ADT), a detectable EOR PSA was more strongly associated with PCSS than initial NCCN risk level (EOR PSA: HR 5.89, 95% CI 2.37–14.65, p<0.001; NCCN risk level: HR 2.01, 95% CI 0.74–5.42, p=0.168). Main study limitations are retrospective study design and associated biases. CONCLUSIONS: EOR PSA was significantly associated with survival endpoints in men who received treated with definitive radiation and ADT. Whether the EOR PSA can be used to modulate treatment intensity merits further investigation. 2017-01-17 2017-06 /pmc/articles/PMC5429233/ /pubmed/28094250 http://dx.doi.org/10.1038/pcan.2016.67 Text en Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms |
spellingShingle | Article Narang, Amol K. Trieu, Janson Radwan, Noura Ram, Ashwin Robertson, Scott P. He, Pei Gergis, Carol Griffith, Emily Singh, Harleen DeWeese, Tate A. Honig, Stephanie Annadanam, Anvesh Greco, Stephen DeVille, Curtiland McNutt, Todd DeWeese, Theodore L. Song, Daniel Y. Tran, Phuoc T. End-of-radiation PSA as a novel prognostic factor in patients undergoing definitive radiation and androgen deprivation therapy for prostate cancer |
title | End-of-radiation PSA as a novel prognostic factor in patients undergoing definitive radiation and androgen deprivation therapy for prostate cancer |
title_full | End-of-radiation PSA as a novel prognostic factor in patients undergoing definitive radiation and androgen deprivation therapy for prostate cancer |
title_fullStr | End-of-radiation PSA as a novel prognostic factor in patients undergoing definitive radiation and androgen deprivation therapy for prostate cancer |
title_full_unstemmed | End-of-radiation PSA as a novel prognostic factor in patients undergoing definitive radiation and androgen deprivation therapy for prostate cancer |
title_short | End-of-radiation PSA as a novel prognostic factor in patients undergoing definitive radiation and androgen deprivation therapy for prostate cancer |
title_sort | end-of-radiation psa as a novel prognostic factor in patients undergoing definitive radiation and androgen deprivation therapy for prostate cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5429233/ https://www.ncbi.nlm.nih.gov/pubmed/28094250 http://dx.doi.org/10.1038/pcan.2016.67 |
work_keys_str_mv | AT narangamolk endofradiationpsaasanovelprognosticfactorinpatientsundergoingdefinitiveradiationandandrogendeprivationtherapyforprostatecancer AT trieujanson endofradiationpsaasanovelprognosticfactorinpatientsundergoingdefinitiveradiationandandrogendeprivationtherapyforprostatecancer AT radwannoura endofradiationpsaasanovelprognosticfactorinpatientsundergoingdefinitiveradiationandandrogendeprivationtherapyforprostatecancer AT ramashwin endofradiationpsaasanovelprognosticfactorinpatientsundergoingdefinitiveradiationandandrogendeprivationtherapyforprostatecancer AT robertsonscottp endofradiationpsaasanovelprognosticfactorinpatientsundergoingdefinitiveradiationandandrogendeprivationtherapyforprostatecancer AT hepei endofradiationpsaasanovelprognosticfactorinpatientsundergoingdefinitiveradiationandandrogendeprivationtherapyforprostatecancer AT gergiscarol endofradiationpsaasanovelprognosticfactorinpatientsundergoingdefinitiveradiationandandrogendeprivationtherapyforprostatecancer AT griffithemily endofradiationpsaasanovelprognosticfactorinpatientsundergoingdefinitiveradiationandandrogendeprivationtherapyforprostatecancer AT singhharleen endofradiationpsaasanovelprognosticfactorinpatientsundergoingdefinitiveradiationandandrogendeprivationtherapyforprostatecancer AT deweesetatea endofradiationpsaasanovelprognosticfactorinpatientsundergoingdefinitiveradiationandandrogendeprivationtherapyforprostatecancer AT honigstephanie endofradiationpsaasanovelprognosticfactorinpatientsundergoingdefinitiveradiationandandrogendeprivationtherapyforprostatecancer AT annadanamanvesh endofradiationpsaasanovelprognosticfactorinpatientsundergoingdefinitiveradiationandandrogendeprivationtherapyforprostatecancer AT grecostephen endofradiationpsaasanovelprognosticfactorinpatientsundergoingdefinitiveradiationandandrogendeprivationtherapyforprostatecancer AT devillecurtiland endofradiationpsaasanovelprognosticfactorinpatientsundergoingdefinitiveradiationandandrogendeprivationtherapyforprostatecancer AT mcnutttodd endofradiationpsaasanovelprognosticfactorinpatientsundergoingdefinitiveradiationandandrogendeprivationtherapyforprostatecancer AT deweesetheodorel endofradiationpsaasanovelprognosticfactorinpatientsundergoingdefinitiveradiationandandrogendeprivationtherapyforprostatecancer AT songdaniely endofradiationpsaasanovelprognosticfactorinpatientsundergoingdefinitiveradiationandandrogendeprivationtherapyforprostatecancer AT tranphuoct endofradiationpsaasanovelprognosticfactorinpatientsundergoingdefinitiveradiationandandrogendeprivationtherapyforprostatecancer |